A popular alternative therapeutic strategy has been the activation of other (non-CFTR) channels/transporters, as it would apply to any individual with CF, irrespective of the CFTR mutations, i.e., a “mutation-agnostic” approach. This evidence concerns the gene CFTR and cystic fibrosis.